Abstract
Introduction
Breast cancer is the most common malignancy in women worldwide and the second cause of death by neoplasia, with an estimated annual incidence of 66.2/ 100000 and a mortality rate around 21.6 deaths/ 100000 in Romania [1] .
For the first time in the 90s, mutations in two genes known as BRCA1 (BRest CAncer) [2] and BRCA2 genes [3] were associated with breast cancer risk. Since then more genes have been associated with breast cancer risk, with an explosive increase after the introduction and large scale use of Next Generation Sequencing (NGS) [4] .
In addition to BRCA1 and BRCA 2 mutations, other genes have been incriminated for breast cancer predisposition, some with high penetrance, such as TP53, PTEN, STK11, CDH1, others with moderate penetrance, like PALB2, CHEK1, ATM, recent studies assigning an increasing importance in the HBOC pathogenesis of the latter [5] .
The technological progress in the last decade has also helped in obtaining a complete immunohistochemistry of the histopathological specimens in a shorter time. A complete histopathological diagnosis with related immunohistochemistry may guide the medical conduct towards a genetic testing that will lead to a more accurate diagnosis and an optimal treatment [6] .
The most well-known association between histology, immunohistochemistry and genetic determinism is that of BRCA1 gene mutations with triple negative breast cancer forms (TNBC) -negative Estrogen receptors (ER), negative Progesterone receptors (PR) and negative Human epidermal growth factor 2 receptor (HER2) [6, 7] .
The importance of this association between BRCA1 mutations and TNBC forms lies in the fact that patients with TNBC have an increased risk of relapse, a poor long term prognosis due to insensitivity to endocrine therapy and anti-HER2 molecular therapies [8] . However, knowing the association of BRCA1 mutations with TNBC can open new opportunities for treatment using the platinum agents or poly ADP ribose polymerase inhibitors (PARP inhibitors) [9] .
In medical literature, there is data regarding the association of less common mutations (e.g. TP53, PALB2, ATM) with certain histological and immunohistochemical features, but the small number of cases and the heterogeneity of the studied population makes it more difficult to establish a precise correlation [10] .
The aim of this study was to assess the association of high and moderate penetrance pathogenic mutations responsible for breast cancer (BRCA1, BRCA2, TP53, PTEN, STK11 CDH1, PALB2, ATM, CHEK2) with specific histopathological and immunohistochemical prognostic factors. The secondary objectives were: to describe the frequency of some genetic variants in the BRCA1 and BRCA2 genes; to determine whether these variants are similar to those in the neighboring countries of Romania (the Eastern European region); and to analyze their correlation with tumor characteristics.
Material and Method

Ethics
This descriptive retrospective study was conducted with the approval no.369 / 14.10.2016 of the ethics committee of "Iuliu Haţieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania. We obtained the informed consent of all patients on the first medical evaluation.
Patients
We enrolled 80 of 108 consecutive patients diagnosed with breast cancer who were addressed for the oncological examination in Oncosurg Surgical Oncology Clinic, from Cluj-Napoca between January 2015 and December 2016 and met the 2016 National Comprehensive Cancer Network (NCCN) criteria for genetic testing [11] . All the patients had a histopathological diagnosis carried out through a Tru-Cut Needle Biopsy in our clinic.
Of the 28 patients excluded 10 had Variants with Unknown significance (VUS) in the studied genes, 3 had pathogenic mutations in low penetrance genes (RAD50, MLH1, MSH6+MUTYH) 15 had mutations in other genes (3 mutations in each BARD1 and PMS2 genes, 2 mutations in each of the RAD 50, BLM genes and 1 mutation in each MLH1, MSH2, MSH6, RAD51C, MEN1 genes).
Histopathology and immunohistochemistry
The pathological examination was conducted in the same laboratory (Santomar Oncodiagnostic) and included the histological type, grade, lymphovascular space invasion and immunohistochemical (IHC) evaluation of estrogen receptor (ER) status, progesterone receptor (PR) status (Allred score), human epidermal growth factor 2 receptor (HER2) gene expression and Ki67 proliferation index.
The histopathological examination was performed with hematoxylin and eosin stain. The immunohistochemical tests were performed using 4-micron-thickness sections of histological specimens fixed in 10% neutral buffered formalin (NBF). Staining was done automatically on a BenchMark ULTRA system (Ventana ™, Roche), using an OptiView™ amplification kit.
The following primary antibodies were used: ER (clone 6F11, Novocastra™ at a 1/40 dilution, an antigen exposure with the CC1 solution); RP (clone 16, Novocastra™ at a 1/250 dilution, an antigen exposure with the CC1 solution); HER2 (clone 4B5, RTU, Ventana™ an antigen exposure with the CC1 solution); Ki67 (clone MIB1, 1/600 dilution, an antigen exposure with the CC1 solution); E-cadherin (clone 35B5, Novocastra™ 1/50 dilution, an antigen exposure with the CC1 solution).
In cases with HER2 ambiguity (2+) determined by immunohistochemistry, chromogenic or fluorescence in situ hybridization was carried out. Chromogenic dual In Situ Hybridization (DISH) was performed automatically on a BenchMark ULTRA system (Ventana™, Roche) with INFORM™ Dual ISH system 800-4422 (Ventana™) kit. Fluorescense In Situ Hibridization (FISH) was performed using a Path vision HER-2 DNA Probe Kit from ABBOT™. The FISH technique was performed with CytoVision DM2500 capture station from Leica Biosystems™.
Genetic testing
Each patient was approached for genetic testing after the histological diagnosis, prior to any other oncological treatments (chemotherapy or hormonal therapy). Genomic DNA was prepared from 5-10 ml of peripheral blood.
Multigene [12] . All targeted regions were sequenced with ≥100x depth. This assay targets all coding regions of the indicated transcript, 10 base pairs of flanking intronic sequence, and specific intronic and intragenic genomic regions demonstrated to be causative of disease. However, for some genes only targeted loci were analyzed. The presence of large genomic rearrangements was investigated using MLPA (Multiplex Ligation -dependent Probe Amplification to Probe Amplification -highly specific chromosome region of interest; [13] ).
All the genetic tests were conducted in GeneKor Laboratories, Greece.
Statistics
Data are expressed as median and interquartile range ((Q1-Q3) where Q1 = first quartile, Q3 = third quartile range) for continuous variables that proved not to follow the normal distribution (tested with Shapiro Wilk test). The comparisons between groups on quantitative data not normally distributed were analyzed with Mann-Whitney test. We used absolute and relative frequencies to express categorical comparisons and Chi-square family tests for proportion to compare frequencies between different groups. A p value of less than 0.05 was considered to indicate statistical significance; all tests were two-tailed. The statistical analysis was performed with the statistical package Statistic for Windows (v. 8, StatSoft, Tusla, USA). Graphical representation of the distribution of immunohistochemical characteristics by group was done using the approach proposed by Weissgerber et al. [14] .
Results
During the analyzed period, 108 patients with breast cancer were eligible for testing and 80 were included in the study (41 with deleterious variants and 39 without any mutation). Of the 41 breast cancer cases, 26 were caused by mutations in the BRCA1 and BRCA2 genes, the rest being due to mutations in the genes CHEK2 (6 cases), PALB2 (5 cases), ATM (2 cases) and TP 53 (2 cases).
Patient and tumor characteristics according to mutation are summarized in Tables 1 and 2 .
We did not identify any pathogenic variants in PTEN, STK11 and CDH1 genes, but only VUS variants which were excluded because of the uncertain risk of breast cancer.
Patients with deleterious variants were diagnosed more frequently with poorly differentiated tumors (G3) (p = 0.0050) compared to those without mutations which had more commonly well-differentiated forms of breast cancer (G1) (p = 0.0120) ( Table 2) . The most poorly differentiated tumors (G3) were in the BRCA1 mutation group (68.42%) and especially in the PALB2 group (80%) ( Table 2 ).
In the group of patients with deleterious variants the prevalent histology was invasive ductal carcinoma in 97.5% of cases and in one case the histology was invasive lobular carcinoma diagnosed in a CHEK2 mutation carrier with bilateral breast carcinoma.
A quarter of patients with CHEK2 mutations had bilateral carcinoma (2 out of 6 patients) ( Table 2) . Significant differences were identified for ER (%) (p=0.0051), PR (%) (p= 0.0004), and Ki67 (%) (p=0.0010) when the BRCA1 group was compared to subjects with negative mutations (Table 3, Figure 1A, 1B, 1C) . No other significant differences for comparisons of the other gene mutations groups with negative mutation subjects were observed (p>0.05) ( Table 3 , Figure 1A, 1B, 1C) . BRCA1 c.3607C>T mutation was diagnosed in seven patients, followed by mutations c.5266dupC (4 cases) and c.181T>G (2 cases). BRCA1 c.3607C>T mutation was the most common in the studied group and it was associated with TNBC type (p<0.0001) in six of these cases (Table 4) .
Of the 41 patients with pathogenic mutations, 5 had mutations in a second gene (12.2%), 2 cases involving BRCA1 gene (associated MEN gene and MUTYH gene), 2 cases involving CHEK2 gene (associated BLM gene and RAD50 gene) and 1 case involving BRCA2 gene (ATM gene) ( Table 4 ). In one case a mutation in CHEK2 gene was associated with VUS mutations in other 2 genes (ATM and BLM) ( Table 4) .
Discussion
This study provides information regarding the main deleterious variants with high and moderate penetrance involved in the pathogenesis of breast cancer in the population of North Western Romania, being the first study of its kind to our knowledge. It also provides information regarding the immunohistochemical features of the breast tumors in the mutation carriers, demonstrating that the association of some immunohistochemical features with certain mutations may entitle us to a genetic testing in some situations.
Recent studies emphasize the pathogenic implication of certain genes, such as PALB2 [15] and CHEK2 [16] that were previously considered to have a moderate penetrance and a minor role in breast cancer. The value in round brackets is the number of cases and it is provided when it is >1
BRCA1
Our results showed an association of BRCA1 mutations with a low percentage of ER, PR, an increased Ki67 index and a HER2 negative status when compared to the negative mutation group (Table 1, Figure 1) . The results are similar to those published by Mavaddat et al. in a study conducted on 3797 patients with breast cancer and positive BRCA1 mutations, their immunohistochemical analysis revealing that 78% were ER-negative; 79% were PR-negative; 90% were HER2-negative and 69% were TNBC [7] . In another study from Poland authors concluded that TNBC forms of breast cancer occur in up to 80% of patients with positive BRCA1 mutations [17] .
Also, patients with pathogenic BRCA1 mutations associated poorly differentiated tumors (13 cases) or moderately differentiated tumors (6 cases), the results being similar to those in the literature [17] .
Within the BRCA1 group in our study, we identified the BRCA1 c.3607C>T mutation in 7 cases, BRCA1 c.5266dupC mutation in 4 cases and BRCA1 c.181T>G mutation in 2 cases (Table 4 ). The BRCA1 c.5266dupC and c.181T>G mutations were reported to be present in the north-eastern Romanian population in the only two studies conducted so far in our country [18, 19] .
The BRCA1 c.3607C>T mutation was the most frequent variant reported, and has not been reported to date in the Romanian population. Furthermore, this mutation was associated with TNBC in 6 cases and all patients were from cities located in north-western Romania. This sequence change creates a premature translational stop signal at codon 1203 (p. Arg1203*) resulting in an absent or disrupted protein product [20] .
BRCA2
BRCA2 positive breast tumors behave as sporadic breast carcinoma variants, usually expressing ER and PR, unlike positive BRCA1 cancers as demonstrated in our study, where only one patient was diagnosed with TNBC (BRCA2 c.9371A>T) ( Table 4) . Similar results were obtained by Mavaddat et al. who examined 2392 patients with breast cancer and positive BRCA2 mutation and concluded that 23% were ER-negative, 36% were PR-negative, 87% were HER-negative and only 16% were triple-negative [7] .
Patients with breast cancer and pathogenic BRCA2 mutations had histological patterns with a lower proliferation index compared to other classes of mutations being similar to sporadic breast cancer.
In our BRCA2 group we diagnosed 7 mutation of which 3 cases had c.8755-1G>A mutation, 3 cases had c.9371A>T and c.1528G>T in one case (Table 4) . BRCA2 c.8755-1G>A mutation was described as pathogenic in a Czech report from 2008 [21] and BRCA2 c.9371A>T was described in several studies from Poland [22] , but never reported in Romanian population.
CHEK2
Patients with CHEK2 mutations had increased levels of ER, similar to those from the group with negative mutation, but with lower values of RP, especially for the 3 cases with CHEK2 c.470T> C mutation, where PR ranged between 0-5%. Data from the literature argue that CHEK2 mutations are associated with ER-positive types according to a study from 2009 conducted on Polish population [23] , which is supported also by a recent article stating that the carriers of CHEK2 mutations associate luminal tumors rather than TNBC [9] .
Although some studies associate CHEK2 c.470T> C variant with invasive lobular carcinoma [24] , in our study all the 3 patients carrying this mutation were diagnosed with invasive ductal carcinoma.
HER2 was negative in 5 of the 6 cases, this data being in accordance with other studies on patients with CHEK2 mutations and breast cancer (Table 4) [25] .
Of the 6 patients with CHEK 2 mutations, 2 patients had bilateral breast carcinoma. Although this finding was interesting, due to the limited number of cases we cannot have a firm conclusion of this association, further studies being needed to clear up this question ( Table  2 ). This possible correlation can be argued by a Danish study from 2014, in which the authors claim an increased risk of contralateral breast cancer in patients CHEK2, but this risk was assessed only for 1100delC mutation which is the most common pathogenic variant of this gene [26] .
PALB2
The subjects with PALB2 mutation from our study had the absence of HER2 expression as immunohistochemical characteristic, two of them were TNBC (Table 2 and 3) .
Even though it did not reach statistical significance, it can be observed that the Ki 67 proliferation index is the highest in this group, even higher than in the BRCA1 mutation group (Table  3) . Furthermore, in 80% of cases, PALB2 mutations were associated with poorly differentiated histological patterns suggesting an increased aggression and a worse outcome (Table 2) . These results are consistent with other studies conducted on breast cancer patients with deleterious PALB2 mutations, which showed an association with TNBC in 33% [27] to 54% of cases, and proved that PALB2 mutation carriers had a worse prognosis and lower survival rates than other pathogenic mutations [28] . In a review from 2015 which totaled 1824 patients with TNBC from 12 studies, 1.2% of patients had deleterious variants in PALB2 gene [29] .
TP53
The 2 patients with TP53 c.469G>T mutation, had the overexpression of HER2 as immunohistochemical characteristic (Table 3 and 4) . This observation is supported by other studies that have shown that breast cancer patients with positive TP53 mutation can associate HER2 -overexpressing forms in up to 82% of cases [30, 31] .
Our results are consistent with those of Bougeard et al. who, in a study published in 2015, conducted on 127 breast cancer patients and positive TP53 mutations reported that HER 2 alone was positive in 55% of cases and 37% of cases were triple positive [31] .
ATM
The 2 patients with ATM mutations had positive ER, PR and HER2 was positive in one case (Table 3 and 4) .
Currently there are no available data about the correlation between tumor pathology subtype and ATM mutations carriers.
Only a few studies have demonstrated an association between the presence of ATM mutations in patients with breast carcinoma and HER2 overexpression both in vivo and in vitro [32, 33] , but the studies on this gene are still at the beginning.
Conclusion
Our research revealed a new BRCA1 mutation which has not been reported to date in the North-Western Romanian population, BRCA1 c.3607C>T, as the most frequent in this population. To date, the only studies conducted in this population argue that c.5266dupC is the most common variant in this region. The BRCA1 c.3607C> T variant associates TNBC type, which is consistent with the general immunohistochemical profile of patients with breast cancer and positive BRCA1 mutation.
Regarding BRCA2 mutations both c.8755-1G>A and c.9371A>T variants were never described in Romanian population and the data from the Eastern European countries for these two mutations are confined, the immunohistochemical pattern being similar to the sporadic forms of breast cancer.
For the rest of the mutations our results regarding their correlation with immunohistochemical features were similar to the data reported by other studies, but the small number of cases makes it difficult to establish some pertinent conclusions. Subsequent studies on a larger number of patients will be able to clarify whether CHEK2 mutations are associated with multifocal or bilateral forms, or whether ATM and TP53 mutations have the overexpression of HER2 as an immunohistochemical feature.
The main limitation of our study is that it is a retrospective study addressing only the North-Western region of Romania. Maybe a future multicenter study addressing more regions in Romania will gather more pathogenic variants that could create the premises for stronger conclusions.
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